|5.||Coronary Artery Disease (Coronary Atherosclerosis)
|1.||Kang, Jung Chaee: 5 articles (07/2013 - 10/2004)|
|2.||Hong, Young Joon: 5 articles (07/2013 - 10/2004)|
|3.||Jeong, Myung Ho: 5 articles (07/2013 - 10/2004)|
|4.||Beltrame, John F: 4 articles (05/2014 - 01/2002)|
|5.||Kim, Kye Hun: 4 articles (07/2013 - 10/2004)|
|6.||Park, Jong Chun: 4 articles (07/2013 - 10/2004)|
|7.||Kim, Ju Han: 4 articles (07/2013 - 10/2004)|
|8.||Cho, Jeong Gwan: 4 articles (07/2013 - 10/2004)|
|9.||Park, Hyung Wook: 4 articles (07/2013 - 10/2004)|
|10.||Ahn, Youngkeun: 4 articles (07/2013 - 08/2007)|
|1.||Verapamil (Calan)FDA LinkGeneric
01/01/2013 - "In conclusion, the no-reflow phenomenon following primary PCI in patients with STEMI is significantly improved by intracoronary administration of verapamil which is useful to reduce cardiovascular events during operation."
01/01/2002 - "The reasons for early preventive use of intracoronary introduction of verapamil and other drugs in the presence of risk of development of no-reflow phenomenon are presented. "
06/01/1994 - "In a prior small series of cases, this "no-reflow" phenomenon appeared to be promptly reversed by the intra-coronary administration of verapamil. "
01/01/2013 - "The present study evaluated the efficacy of intracoronary administration of verapamil to attenuate the no-reflow phenomenon following the primary percutaneous coronary intervention (PCI) in patients with the ST-segment elevation acute myocardial infarction (STEMI). "
11/01/2002 - "Treatment of no-reflow phenomenon with verapamil after primary stent deployment during myocardial infarction."
|2.||Urokinase-Type Plasminogen Activator (Urokinase)FDA Link
10/01/2010 - "Treatment of an Angioguard XP filter with a urokinase solution is effective in preventing pore occlusion and may reduce occurrence of the slow-flow phenomenon."
06/01/1989 - "In order to evaluate the effect of fibrinolytic drugs on the "no reflow" phenomenon, urokinase was infused prior to reperfusion, and after 5 hours of ischemia, in a separate group of animals. "
12/01/1996 - "In a patient with a complicated history of coronary artery disease, a restenotic lesion inside a Gianturco-Roubin flex stent was relieved by angioplasty and deployment of three 10 mm Palmaz P-104 "biliary" stents, with urokinase and verapamil used to prevent thromboembolism and the no-reflow phenomenon. "
03/01/1987 - "We compared the efficacy of intra-arterial infusion of urokinase, a fibrinolytic agent, with that of intra-arterial infusion of nitrendipine, a peripheral calcium-channel blocking agent, in preventing the no-reflow phenomenon in rats after prolonged ischemia at room temperature. "
05/09/2000 - "Adenosine adjunct to primary PTCA ameliorates flow, prevents the no-reflow phenomenon, improves ventricular function, and is associated with a more favorable clinical course."
01/01/2004 - "In small-scale studies in patients with acute MI, treatment with adenosine has been associated with smaller infarcts, less no-reflow phenomenon and improved LV function. "
01/01/2008 - "In view of adenosine's extremely short half-life in blood, the continuous administration of adenosine into the distal vascular bed throughout percutaneous coronary intervention may further improve outcomes by reversing or preventing the no-reflow phenomenon."
11/01/2007 - "In conclusion, adenosine's numerous cardioprotective effects, including attenuation of the "no-reflow" phenomenon, support its use in high risk STEMI undergoing reperfusion."
10/01/2001 - "Use of intracoronary adenosine for the management of slow-no-reflow phenomenon during percutaneous interventions."
|4.||Nitroprusside (Sodium Nitroprusside)FDA LinkGeneric
03/16/2004 - "Sodium nitroprusside is one of several agents considered effective for treating the no-reflow phenomenon during acute coronary interventions. "
10/01/2004 - "Intracoronary bolus injection of nitroprusside using a 3 ml syringe appears to be a feasible, safe, and effective technique for the management of slow/no-reflow phenomenon complicating primary PCI."
01/01/2014 - "The objective of this study was to evaluate the clinical efficacy and safety of nitroprusside injection for preventing the slow-flow/no-reflow phenomenon after percutaneous coronary intervention (PCI). "
11/20/2009 - "This study aimed to evaluate intracoronary nitroprusside in the prevention of the no-reflow phenomenon in AMI. "
08/01/2014 - "Effect of intracoronary nitroprusside in preventing no reflow phenomenon during primary percutaneous coronary intervention: a meta-analysis."
11/01/2005 - "Moreover, the decrease in platelet and leukocyte count in the treated group might express a reduced no-reflow phenomenon and a better reperfusion, limiting endothelial injury from oxygen radical production."
07/01/1995 - "Role of oxygen radical-induced no-reflow phenomenon."
05/15/1987 - "Capillary plugging by granulocytes appears to be the mechanism responsible for the no-reflow phenomenon, and together with oxygen free radical formation and lysosomal enzyme activity may constitute the origin for ischemic injury as well as other microvascular occlusive diseases."
09/01/1978 - "The poor survival results in the SH group; two of 12 are attributed to the low oxygen availability possibly triggering the no-reflow phenomenon which prevents reversibility of the myocardial ultrastructural damage and ultimately the functional integrity of the ventricle."
09/01/1978 - "The effect of blood oxygen content and the no-reflow phenomenon on the subendocardial ultrastructural reversibility following anoxic arrest using hemodilution variables in the experimental model."
|6.||Nitric Oxide (Nitrogen Monoxide)FDA Link
04/01/2001 - "The objective of this study was to test the hypothesis that the intracoronary administration of a direct donor of nitric oxide is a safe and effective method to treat impaired blood flow (no-reflow phenomenon) that occurs during percutaneous transluminal coronary interventions (PTCI). "
05/01/2014 - "The role of nitric oxide in the coronary slow flow phenomenon."
06/01/2003 - "The reduced availability of nitric oxide leads to the adhesion of neutrophils to the vascular endothelium, platelet aggregation and, with the contribution of endothelin, vasoconstriction, which are responsible for the "no-reflow" phenomenon. "
06/01/2005 - "Effects of the nitric oxide donor nitroprusside on no-reflow phenomenon during coronary interventions for acute myocardial infarction."
|7.||Adenosine Triphosphate (ATP)IBA
10/02/2002 - "The K(ATP) channel activation, but not NO, is a major mechanism of protection against microvascular injury, causing the no-reflow phenomenon in the heart. "
10/02/2002 - "K(ATP) channel opening is an endogenous mechanism of protection against the no-reflow phenomenon but its function is compromised by hypercholesterolemia."
10/02/2002 - "This study aimed to clarify the role of adenosine triphosphate-sensitive K(+) (K(ATP)) channels in the no-reflow phenomenon and in its extension by hypercholesterolemia. "
10/01/2003 - "Conversely, blockade of the K(ATP) channel aggravates microvascular necrosis and the no-reflow phenomenon after ischemia/reperfusion, resulting in augmentation of post-infarct ventricular dysfunction. "
|8.||eptifibatide (Integrilin)FDA Link
12/01/2005 - "The no-reflow phenomenon disappeared after intracoronary eptifibatide infusion and aspiration of the slugging contrast from the vein. "
01/01/2013 - "According to the present study, although SK is more effective than eptifibatide in resolution of thrombosis and clots, rescue PCI did not differ from PPCI in terms of the incidence of no-reflow phenomenon or short-term complications."
06/01/2013 - "To observe the clinical efficacy of treating patients with coronary slow flow phenomenon by Yiqi Huoxue Recipe (YHR) combined Western drugs, thus providing clinical evidence for further studies. "
06/01/2013 - "[Treatment of sixty-one patients with coronary slow flow phenomenon by yiqi huoxue recipe combined Western drugs: a clinical research]."
|10.||abciximab (ReoPro)FDA Link
01/01/2008 - "'Rescue' administration of abciximab is an effective option for the treatment of the no-reflow phenomenon determining significant prognostic improvements."
02/01/2008 - "Abciximab was used to treat the no-reflow phenomenon, which occurred during insertion of three sequential Taxus coronary artery stents. "
01/01/2008 - "We retrospectively selected 38 patients who developed the no-reflow phenomenon after primary angioplasty: 18 received post-procedural abciximab, 20 age- and sex-matched patients who did not receive abciximab were considered as concurrent controls. "
01/01/2008 - "We sought to investigate the effect of post-procedural abciximab on clinical outcome of patients presenting the no-reflow phenomenon after primary angioplasty. "
01/01/2008 - "Beneficial effect of post-procedural abciximab in patients undergoing primary coronary angioplasty and presenting with the no-reflow phenomenon."
09/30/2005 - "Distal protection using FilterWire EX has been shown to be effective in reducing the incidence of debris embolization and no-reflow phenomenon in saphenous vein graft (SVG) intervention. "
06/01/2012 - "The aim of this study was to investigate the relation between intravascular ultrasound (IVUS) findings and the no-reflow phenomenon and long-term outcome after percutaneous coronary intervention (PCI) of saphenous vein graft (SVG) lesions. "
08/01/2012 - "Slow flow and no-reflow phenomenon (SF-NR) in saphenous vein grafts (SVG) stenting is related to the occurrence of distal plaque embolization, platelet activation and microvascular vasospasm. "
05/01/2010 - "Treatment of vein graft disease remains a challenge in interventional cardiology because of the risk of embolization and no-reflow phenomenon. "
01/01/2008 - "Herein, we report the cases of 4 patients who developed the no-reflow phenomenon after elective percutaneous coronary intervention to their native coronary arteries and saphenous vein grafts. "
|2.||Angioplasty (Angioplasty, Transluminal)
05/01/1998 - "The current study shows that the no-reflow phenomenon is not uncommon after angioplasty; no-reflow appears higher than the previous reports for both modalities of treatment."
06/01/2012 - "We describe a case in which 'no-reflow' phenomenon developed after DEB angioplasty of a DES ISR lesion. "
03/01/2006 - "An association has been reported between direct stenting in primary angioplasty and low incidences of the no-reflow phenomenon and distal embolization. "
06/01/2005 - "The so called no-reflow phenomenon mainly occurs in the presence of highly thrombotic lesions, especially during primary angioplasty and it represents a negative prognostic factor of the outcome of AMI patients treated with angioplasty. "
01/01/2004 - ""No-reflow" phenomenon during percutaneous carotid angioplasty in a scleroderma patient."
05/01/2007 - "Several studies have shown that rotational atherectomy (RA) is associated with higher rates of the slow-flow phenomenon and that ablated particles may be the possible cause. "
11/15/2006 - "In rotational atherectomy, the slow-flow/no-reflow phenomenon is a common complication, which usually results in myocardial injury. "
06/01/2004 - "We sought to evaluate the safety and effectiveness of a burr size/reference artery diameter (RAD) ratio <0.7 in rotational atherectomy in order to reduce the distal embolization and then to analyze the procedural and peri-procedural no-reflow phenomenon. "
12/01/2002 - "A major limitation of the rotational atherectomy (RA) procedure is the occurrence of the no-reflow/slow flow phenomenon and the optimal strategy is still evolving. "
08/01/1996 - "Clinical and postmortem outcome of "no-reflow' phenomenon in a patient treated with rotational atherectomy."
05/01/2015 - "We would suggest careful OCT examination is warranted to confirm development of neoatherosclerosis within the stent, and distal protection device should be considered to prevent slow flow phenomenon even in a patient with very late ISR."
08/01/2011 - "Aggressive stent deployment can, on the other hand, cause distal embolisation and the no-reflow phenomenon. "
10/01/2007 - "The angiographic no-reflow phenomenon was defined as a decrease in final TIMI flow grade compared with TIMI flow grade before stent implantation. "
04/01/2006 - "This case-report describes no-reflow phenomenon in a patient undergoing elective PCI in the right coronary artery, occluded due to restenosis in implanted stent. "
02/01/2006 - "In conclusion, high atherothrombotic burden and decreased plaque volume as detected by IVUS may be risk factors for development of the no-reflow phenomenon during stent implantation in patients with AMI."
12/01/2006 - "Through our series of fifteen digital replantations, having suffered a "no reflow phenomenon", we are going to present the fibrinolytic protocol we used and the promising results we obtained. "
03/01/2010 - "Among the relative contraindications to replantation are prolonged warm ischaemia time, since an obstruction to blood reflow ('no-reflow phenomenon') may occur in amputated parts that are subjected to more than 6h of warm ischaemia. "
10/01/1992 - "The no-reflow phenomenon is one of the factors that increase morbidity in flap and replantation surgery. "
05/01/1983 - "Although further studies are necessary for clinical application, it is suggested that the FC immersion technique has a definite potential for prevention of the no-reflow phenomenon in tissue transplantation and replantation surgery."
06/01/2005 - "The event eventually responsible for tissue death is the no-reflow phenomenon and its management is a challenge for the surgeon dealing with replantation or transplantation. "